首页 › 基金 › Ranger Investment Management, L.P. › PTGX

Ranger Investment Management, L.P. 对 PTGX 的持仓历史

PROTAGONIST THERAPEUTICS INC · 医疗保健

Ranger Investment Management, L.P. 在 Q3 2026 的 13F 申报中披露持有 PTGX(PROTAGONIST THERAPEUTICS INC)82,362 股,市值约 US$11.6M,约占其申报组合的 1.09%,在其申报持仓中市值排名第 36 位。 Ranger Investment Management, L.P. 于 Q3 2026 首次申报该持仓。

最新持仓 (Q3 2026)82.36K 股
申报持仓市值$11.60M
组合权重1.09%
首次申报Q3 2026
最近变动新进
更新于2026-11-13

最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR

Ranger Investment Management, L.P. 对 PTGX 的持仓演变

Ranger Investment Management, L.P. 于 Q3 2026 首次披露 PTGX 持仓:82,362 股(约 US$11.6M)。

逐季持仓明细

季度股数金额变化
Q3 2026 82.36K $11.60M 新进

关于 PTGX 与 13F 数据

PTGX(PROTAGONIST THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 51 只申报持有 PTGX,申报仓位最大的包括:法拉龙资本管理 (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 PTGX 的基金

查看 PTGX 的全部基金持有人 →

常见问题

How long has Ranger Investment Management, L.P. held PTGX?

Ranger Investment Management, L.P. has disclosed PTGX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is Ranger Investment Management, L.P.'s current position in PTGX?

As of Q3 2026, Ranger Investment Management, L.P. holds 82.36K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $11.60M, representing 1.09% of its reported portfolio and ranking #36.

Has Ranger Investment Management, L.P. been buying or selling PTGX?

In the latest 13F filing (Q3 2026), Ranger Investment Management, L.P. newly opened its position in PTGX.

Which other funds hold PTGX?

Other major institutional holders of PTGX include 法拉龙资本管理, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.